Haisco Pharmaceutical (688302.SH): The final analysis results of the clinical phase IIa trial of the drug HP515 for the treatment of metabolic associated fatty liver disease (MASH) have been achieved.

Zhitong finance and economics APP news, Hai Chuang Pharmaceutical (688302.SH) announced that the final analysis results of the phase IIa clinical trial of HP515 tablets, a type 1 innovative drug developed independently by the company for the treatment of metabolic-associated fatty liver disease (MASH, formerly known as nonalcoholic fatty liver disease (NASH)), have reached the primary endpoint and key secondary endpoints. The trial results indicate that HP515 tablets can significantly improve liver lipid metabolism, improve blood lipid abnormalities, and have good overall safety.